Skip to main content Accessibility help
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 3
  • Print publication year: 2010
  • Online publication date: August 2010

17 - Latent inhibition in schizophrenia and schizotypy: a review of the empirical literature

from Current topics in latent inhibition research



Schizophrenia is a severe neuropsychiatric disorder of unknown aetiology. The condition is clinically heterogeneous and affects virtually all areas of life, often resulting in disabling cognitive, perceptual, and emotional symptoms. The symptoms of schizophrenia are generally classified as positive (e.g. hallucinations and delusions), negative (e.g. anhedonia, alogia, thought paucity) and cognitive (e.g. thought disorder, bizarre thinking). The disease course is often chronic and the financial cost on the health-care system and society is tremendous, in addition to the personal consequences of the illness for friends and family of sufferers (Mangalore & Knapp,2007; McEvoy, 2007). Tragically, a substantial number of patients commit suicide.

The most successful treatments for schizophrenia that are currently prescribed are pharmacological, and most of these involve blockade of striatal dopamine receptors (Kapur & Remington, 2001). These treatments are successful in reducing the acute symptoms of the condition but provide no cure; accordingly, the need for a better understanding of the aetiology and pathophysiology of schizophrenia and the development of novel treatments is considerable. Drug development draws on many experimental strategies as well as on serendipity (Carpenter & Koenig, 2008; Javitt et al., 2008); translational models such as latent inhibition (LI) play an important role in the strategic effort to develop new treatments (Weiner, 2003). Indeed, a wealth of animal data exist that support the utility of the LI paradigm in studies of antipsychotic treatments (e.g., Weiner, this volume).

Agid, O., Kapur, S., Warrington, L., Loebel, A., & Siu, C. (2008). Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders. Schizophrenia Research, 102, 241–248.
Allan, L. M., William, J. H., Wellman, N. A., et al. (1995). Effects of tobacco smoking, schizotypy, and number of pre-exposures on latent inhibition in healthy subjects. Personality and Individual Differences, 19, 893–902.
Arad, M., & Weiner, I. (2008). Fluctuation of latent inhibition along the estrous cycle in the rat: modeling the cyclicity of symptoms in schizophrenic women?Psychoneuroendocrinology, 33, 1401–1410.
Arranz, M. J., & Leon, J. (2007). Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Molecular Psychiatry, 12, 707–747.
Baruch, I., Hemsley, D. R., & Gray, J. A. (1988a). Differential performance of acute and chronic schizophrenics in a latent inhibition task. Journal of Nervous & Mental Diseases, 176, 598–606.
Baruch, I., Hemsley, D. R., & Gray, J. A. (1988b). Latent inhibition and “psychotic proneness” in normal subjects. Personality and Individual Differences, 9, 777–783.
Bentall, R. P., Claridge, G. S., & Slade, P. D. (1989). The multidimensional nature of schizotypal traits: a factor analytic study with normal subjects. British Journal of Clinical Psychology, 28, 363–375.
Bleuler, E. (1950). Dementia Praecox or the Group of Schizophrenias (J. Zinkin, Trans.). New York: International Universities Press.
Braunstein-Bercovitz, H. (2000). Is the attentional dysfunction in schizotypy related to anxiety?Schizophrenia Research, 46, 255–267.
Braunstein-Bercovitz, H., Hen, I., & Lubow, R. E. (2004). Masking task load modulates latent inhibition: support for a distraction model of irrelevant information processing by high schizotypals. Cognition and Emotion, 18, 1135–1144.
Braunstein-Bercovitz, H., & Lubow, R. E. (1998). Are high-schizotypal normal participants distractible or limited in attentional resources? A study of latent inhibition as a function of masking task load and schizotypy level. Journal of Abnormal Psychology, 107, 659–670.
Buckley, P. F., Miller, B. J., Lehrer, D. S., & Castle, D. J. (2009). Psychiatric comorbidities and schizophrenia. Schizophrenia Bulletin, 35, 383–402.
Burch, G. S., Hemsley, D. R., & Joseph, M. H. (2004). Trials-to-criterion latent inhibition in humans as a function of stimulus pre-exposure and positive-schizotypy. British Journal of Psychology, 95, 179–196.
Calkins, M. E., Iacono, W. G., & Ones, D. S. (2008). Eye movement dysfunction in first-degree relatives of patients with schizophrenia: a meta-analytic evaluation of candidate endophenotypes. Brain and Cognition, 68, 436–461.
Carpenter, W. T., & Koenig, J. I. (2008). The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacology, 33, 2061–2079.
Chapman, L. J., Chapman, J. P., & Kwapil, T. R. (1995). Scales for the measurement of schizotypy. In Raine, A., Lencz, T., & Mednick, S. A. (Eds.), Schizotypal Personality. New York: Cambridge University Press.
Claridge, G. S., & Broks, P. (1984). Schizotypy and hemisphere function. I. Theoretical considerations and measurement of schizotypy. Personality and Individual Differences, 5, 633–648.
Cohen, E., Sereni, N., Kaplan, O., et al. (2004). The relation between latent inhibition and symptom-types in young schizophrenics. Behavioural Brain Research, 149, 113–122.
Costa, P. T., & McCrae, R. R. (1992). Revised NEO Personality Inventory: Professional Manual. Florida: Psychological Assessment Resources Inc.
Casa, L. G., Ruiz, G., & Lubow, R. E. (1993). Latent inhibition and recall/recognition of irrelevant stimuli as a function of pre-exposure duration in high and low psychotic-prone normal subjects. British Journal of Psychology, 84, 119–132.
Della Casa, V., Höfer, I., Weiner, I., & Feldon, J. (1999). Effects of smoking status and schizotypy on latent inhibition. Journal of Psychopharmacology, 13, 45–57.
Dunn, L. A., Atwater, G., & Kilts, C. D. (1993). Effects of antipsychotic drugs on latent inhibition: sensitivity and specificity of an animal behavioural model of clinical drug action. Psychopharmacology, 112, 315–323.
Evans, L. H., Gray, N. S., & Snowden, R. J. (2007). A new continuous within-participants latent inhibition task: examining associations with schizotypy dimensions, smoking status and gender. Biological Psychology, 74, 365–373.
Eysenk, H. J. (1967). The Biological Basis of Personality. Springfield, IL: Charles C Thomas.
Eysenck, H. J., & Eysenck, S. B. G. (1975). Manual of the Eysenck Personality Questionnaire. London: Hodder and Stoughton.
Eysenck, H. J., & Eysenck, S. B. G. (1991). Manual of the Eysenck Personality Scales. London: Hodder and Stoughton.
Fanous, A. H., Neale, M. C., Gardner, C. O., et al. (2007). Significant correlation in linkage signals from genome-wide scans of schizophrenia and schizotypy. Molecular Psychiatry, 12, 958–965.
Gal, G., Barnea, Y., Biran, L., et al. (2009). Enhancement of latent inhibition in patients with chronic schizophrenia. Behavioural Brain Research, 197, 1–8.
Gottesman, I. I., & Gould, T. D. (2003). The endophenotype concept in psychiatry: etymology and strategic intentions. American Journal of Psychiatry, 160, 636–645.
Gray, J. A. (1998). Integrating schizophrenia. Schizophrenia Bulletin, 24, 249–266.
Gray, J. A., Feldon, J., Rawlins, J. N. P., Hemsley, D. R., & Smith, A. D. (1991). The neuropsychology of schizophrenia. Behavioral and Brain Sciences, 14, 1–84.
Gray, J. A., Kumari, V., Lawrence, N., & Young, A. M. J. (1999). Functions of the dopaminergic innervation of nucleus accumbens. Psychobiology, 27, 225–235.
Gray, N. S., Fernandez, M., Williams, J., Ruddle, R. A., & Snowden, R. J. (2002). Which schizotypal dimensions abolish latent inhibition?British Journal of Clinical Psychology, 41, 271–284.
Gray, N. S., Hemsley, D. R., & Gray, J. A. (1992a). Abolition of latent inhibition in acute, but not chronic, schizophrenics. Neurology Psychiatry and Brain Research, 1, 83–89.
Gray, N. S., Pickering, A. D., Hemsley, D. R., Dawling, S., & Gray, J. A. (1992b). Abolition of latent inhibition by a single 5 mg dose of d-amphetamine in man. Psychopharmacology, 107, 425–430.
Gray, N. S., Pilowsky, L. S., Gray, J. A., & Kerwin, R. W. (1995). Latent inhibition in drug-naive schizophrenics: relationship to duration of illness and dopamine D2 binding using SPET. Schizophrenia Research, 17, 95–107.
Guterman, Y., Josiassen, R. C., Bashore, T. E., Johnson, M., & Lubow, R. E. (1996). Latent inhibition effects reflected in event-related brain potentials in healthy controls and schizophrenics. Schizophrenia Research, 20, 315–326.
Gruzelier, J. (2002). A Janusian perspective on the nature, development and structure of schizophrenia and schizotypy. Schizophrenia Research, 54, 95–103.
Heinrichs, R. W., & Zakzanis, K. K. (1998). Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology, 12, 426–445.
Hemsley, D. R. (1987). An experimental psychological model for schizophrenia. In Hafner, H., Gattaz, W. F. & , W. Janzavik W. (Eds.), Search for the Causes of Schizophrenia. Berlin: Springer, pp. 179–188.
Hemsley, D. R. (1993). A simple (or simplistic?) cognitive model for schizophrenia. Behavior Research and Therapy, 31, 633–645.
Höfer, I., Della Casa, V., & Feldon, J. (1999). The interaction between schizotypy and latent inhibition: modulation by experimental parameters. Personality and Individual Differences, 26, 1075–1088.
Hutton, S. B., & Ettinger, U. (2006). The antisaccade task as a research tool in psychopathology: a critical review. Psychophysiology, 43, 302–313.
Javitt, D. C., Spencer, K. M., Thaker, G. K., Winterer, G., & Hajós, M. (2008). Neurophysiological biomarkers for drug development in schizophrenia. Nature Reviews Drug Discovery, 7, 68–83.
Kaplan, O., Dar, R., Rosenthal, L., et al. (2006). Obsessive-compulsive disorder patients display enhanced latent inhibition on a visual search task. Behavior Research and Therapy, 44, 1137–1145.
Kathmann, N., Recum, S., Haag, C., & Engel, R. R. (2000). Electrophysiological evidence for reduced latent inhibition in schizophrenic patients. Schizophrenia Research, 45, 103–114.
Kapur, S., Arenovich, T., Agid, O., et al. (2005). Evidence for onset of antipsychotic effects within the first 24 hours of treatment. American Journal of Psychiatry, 162, 939–946.
Kapur, S., & Remington, G. (2001). Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biological Psychiatry, 50, 873–83.
Kay, S. R., Fiszbein, P. S., & Opler, L. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261–276.
Kraepelin, E. (1919/1971). Dementia Praecox and Paraphrenia (Barclay, R.M., Trans.). Huntington, NY: Krieger.
Kumari, V., Cotter, P., Mulligan, O., et al. (1999). Effect of d-amphetamine and haloperidol on latent inhibition in healthy male volunteers. Journal of Psychopharmacology, 13, 398–405.
Kumari, V., Das, M., Zachariah, E., Ettinger, U., & Sharma, T. (2005). Reduced prepulse inhibition in unaffected siblings of schizophrenia patients. Psychophysiology, 42, 588–594.
Larrison, A. L., Briand, K. A., & Sereno, A. B. (1999). Nicotine, caffeine, alcohol, and schizotypy. Personality and Individual Differences, 27, 101–108.
Launay, G., & Slade, P. (1981). The measurement of hallucinatory predisposition in male and female prisoners. Personality and Individual Differences, 2, 221–234.
Lenzenweger, M. F. (1998). Explorations in schizotypy and the psychometric high-risk paradigm. In Chapman, L. J., Chapman, J. P., & Fowler, D. C. (Eds.), Progress in Experimental Personality and Psychopathological Research, vol. 16. New York: Springer.
Leumann, L., Feldon, J., Vollenweider, F. X., & Ludewig, K. (2002). Effects of typical and atypical antipsychotics on prepulse inhibition and latent inhibition in chronic schizophrenia. Biological Psychiatry, 52, 729–739.
Lipp, O. V., Siddle, D. A. T., & Arnold, S. L. (1994). Psychosis-proneness in a non-clinical sample. II. A multi-experimental study of ‘attentional malfunctioning’. Personality and Individual Differences, 15, 405–424.
Lipp, O. V., & Vaitl, D. (1992). Latent inhibition in human Pavlovian differential conditioning: effect of additional stimulation after preexposure and relation to schizotypal traits. Personality and Individual Differences, 13, 1003–1012.
Lubow, R. E. (2005). The construct validity of the animal-latent inhibition model of selective attention deficits in schizophrenia. Schizophrenia Bulletin, 31, 139–153.
Lubow, R. E., & Casa, G. (2002). Latent inhibition as a function of schizotypality and gender: implications for schizophrenia. Biological Psychology, 59, 69–86.
Lubow, R. E., Ingberg-Sachs, Y., Zalstein-Orda, N., & Gewirtz, J. C. (1992). Latent inhibition in low and high “psychotic-prone” normal subjects. Personality and Individual Differences, 13, 563–572.
Lubow, R. E., Kaplan, O., Abramovich, P., Rudnick, A., & Laor, N. (2000). Visual search in schizophrenia: latent inhibition and novel pop-out effects. Schizophrenia Research, 45, 145–156.
Lubow, R. E., Kaplan, O., & Casa, G. (2001). Performance on the visual search analog of latent inhibition is modulated by an interaction between schizotypy and gender. Schizophrenia Research, 52, 275–287.
Lubow, R. E., Weiner, I., Scholossberg, A., & Baruch, I. (1987). Latent inhibition and schizophrenia. Bulletin of Psychonomic Society, 25, 464–467.
Mangalore, R., & Knapp, M. (2007). Cost of schizophrenia in England. The Journal of Mental Health Policy and Economics, 10, 23–41.
Marcelis, M., Suckling, J., Woodruff, P., et al. (2003). Searching for a structural endophenotype in psychosis using computational morphometry. Psychiatry Research, 122, 153–167.
Mason, O., Claridge, G., & Jackson, M. (1995). New scales for the assessment of schizotypy. Personality and Individual Differences, 18, 7–13.
McEvoy, J. P. (2007). The costs of schizophrenia. Journal of Clinical Psychiatry, 68, 4–7.
Meehl, P. E. (1989). Schizotaxia revisited. Archives of General Psychiatry, 46, 935–944.
Moser, P. C., Hitchcock, J. M., Lister, S., & Moran, P. M. (2000). The pharmacology of latent inhibition as an animal model of schizophrenia. Brain Research Reviews, 33, 275–307.
Nuechterlein, K. H., & Dawson, M. E. (1984). Information processing and attentional functioning in the developmental course of schizophrenic disorders. Schizophrenia Bulletin, 10, 160–203.
Overall, J. E., & Gorham, D. R. (1962). The Brief Psychiatric Rating Scale. Psychological Reports, 10, 799–812.
Phillips, L. J., Yung, A. R., Yuen, H. P., Pantelis, C., & McGorry, P. D. (2002). Prediction and prevention of transition to psychosis in young people at incipient risk for schizophrenia. American Journal of Medical Genetics, 114, 929–937.
Prasad, K. M., & Keshavan, M. S. (2008). Structural cerebral variations as useful endophenotypes in schizophrenia: do they help construct “extended endophenotypes”?Schizophrenia Bulletin, 34, 774–790.
Raine, A. (1991). The SPQ: a scale for the assessment of schizotypal personality based on DSM-III-R criteria. Schizophrenia Bulletin, 17, 555–564.
Raine, A. (2006). Schizotypal personality: neurodevelopmental and psychosocial trajectories. Annual Review of Clinical Psychology, 2, 291–326.
Raine, A., Reynolds, C., Lencz, T., et al. (1994). Cognitive-perceptual, interpersonal, and disorganized features of schizotypal personality. Schizophrenia Bulletin, 20, 191–201.
Rascle, C., Mazas, O., Vaiva, G., et al. (2001). Clinical features of latent inhibition in schizophrenia. Schizophrenia Research, 51, 149–161.
Reichenberg, A., & Harvey, P. D. (2007). Neuropsychological impairments in schizophrenia: integration of performance-based and brain imaging findings. Psychological Bulletin, 133, 833–858.
Reynolds, G. P. (2007). The impact of pharmacogenetics on the development and use of antipsychotic drugs. Drug Discovery Today, 12, 953–959.
Ruob, C., Weiner, I., & Feldon, J. (1998). Haloperidol-induced potentiation of latent inhibition: interaction with parameters of conditioning. Behavioural Pharmacology, 9, 245–253.
Rust, J. (1989). Rust Inventory of Schizotypal Cognitions Manual. Kent: Psychological Corporation Ltd.
Salamone, J. D., Cousins, M. S., & Snyder, B. J. (1997). Behavioral functions of nucleus accumbens dopamine: empirical and conceptual problems with the anhedonia hypothesis. Neuroscience and Biobehavioral Reviews, 21, 341–359.
Serra, A. M., Jones, S. H., Toone, B., & Gray, J. A. (2001). Impaired associative learning in chronic schizophrenics and their first-degree relatives: a study of latent inhibition and the Kamin blocking effect. Schizophrenia Research, 48, 273–289.
Shadach, E., Feldon, J., & Weiner, I. (1999). Clozapine-induced potentiation of latent inhibition is due to its action in the conditioning stage: Implications for the mechanism of action of antipsychotic drugs. International Journal of Neuropsychopharmacology, 2, 283–291.
Skelley, S. L., Goldberg, T. E., Egan, M. F., Weinberger, D. R., & Gold, J. M. (2008). Verbal and visual memory: characterizing the clinical and intermediate phenotype in schizophrenia. Schizophrenia Research, 105, 78–85.
Snitz, B. E., Macdonald, A. W., & Carter, C. S. (2006). Cognitive deficits in unaffected first-degree relatives of schizophrenia patients: a meta-analytic review of putative endophenotypes. Schizophrenia Bulletin, 32, 179–194.
Stevens, A., Peschk, I., & Schwarz, J. (2007). Implicit learning, executive function and hedonic activity in chronic polydrug abusers, currently abstinent polydrug abusers and controls. Addiction, 102(6), 937–946.
Strauss, J. S. (1969). Hallucinations and delusions as points on continua function. Archives of General Psychiatry, 21, 581–586.
Swerdlow, N. R., Braff, D. L., Hartson, H., Perry, W., & Geyer, M. A. (1996). Latent inhibition in schizophrenia. Schizophrenia Research, 20, 91–103.
Swerdlow, N. R., Hartston, H. J., & Hartman, P. L. (1999). Enhanced visual latent inhibition in obsessive-compulsive disorder. Biological Psychiatry, 45, 482–488.
Swerdlow, N. R., Stephany, N., Wasserman, L. C., et al. (2003). Dopamine agonists disrupt visual latent inhibition in normal males using a within-subject paradigm. Psychopharmacology, 169, 314–320.
Swerdlow, N. R., Stephany, N., Wasserman, L. C., et al. (2005). Intact visual latent inhibition in schizophrenia patients in a within-subject paradigm. Schizophrenia Research, 72, 169–183.
Thaker, G. K. (2007). Schizophrenia endophenotypes as treatment targets. Expert Opinion on Therapeutic Targets, 11, 1189–206.
Thornton, J. C., Dawe, S., Lee, C., et al. (1996). Effects of nicotine and amphetamine on latent inhibition in human subjects. Psychopharmacology, 127, 164–173.
Tsakanikos, E. (2004). Latent inhibition, visual pop-out and schizotypy: is disruption of latent inhibition due to enhanced stimulus salience?Personality and Individual Differences, 37, 1347–1358.
Os, J., Hanssen, M., Bijl, R. V., & Ravelli, A. (2000). Strauss (1969) revisited: a psychosis continuum in the general population?Schizophrenia Research, 45, 11–20.
Vaitl, D., Lipp, O., Bauer, U., et al. (2002). Latent inhibition and schizophrenia: Pavlovian conditioning of autonomic responses. Schizophrenia Research, 55, 147–158.
Haren, N. E., Bakker, S. C., & Kahn, R. S. (2008). Genes and structural brain imaging in schizophrenia. Current Opinion in Psychiatry, 21, 161–167.
Venables, P. H., Wilkins, S., Mitchell, D. A., Raine, A., & Bailes, K. (1990). A scale for the measurement of schizotypy. Personality and Individual Differences, 11, 481–495.
Vollema, M. G., & Bosch, R. J. (1995). The multidimensionality of schizotypy. Schizophrenia Bulletin, 21, 19–31.
Whalley, H. C., Harris, J. C., & Lawrie, S. M. (2007). The neurobiological underpinnings of risk and conversion in relatives of patients with schizophrenia. International Review of Psychiatry, 19, 383–397.
Whalley, H. C., Simonotto, E., Flett, S., et al. (2004). fMRI correlates of state and trait effects in subjects at genetically enhanced risk of schizophrenia. Brain, 127, 478–490.
Williams, J. H., Wellman, N. A., Geaney, D. P., et al. (1997). Haloperidol enhances latent inhibition in visual tasks in healthy people. Psychopharmacology, 133, 262–268.
Williams, J. H., Wellman, N. A., Geaney, D. P., et al. (1998). Reduced latent inhibition in people with schizophrenia: an effect of psychosis or of its treatment?British Journal of Psychiatry, 172, 243–249.
Williams, J. H., Wellman, N. A., & Rawlins, J. N. (1996). Cannabis use correlates with schizotypy in healthy people. Addiction, 91, 869–877.
Weiner, I. (2003). The ‘two-headed’ latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology, 169, 257–297.
Wuthrich, V., & Bates, T. C. (2001). Schizotypy and latent inhibition: non-linear linkage between psychometric and cognitive markers. Personality and Individual Differences, 30(5), 783–798.
Yogev, H., Sirota, P., Gutman, Y., & Hadar, U. (2004). Latent inhibition and overswitching in schizophrenia. Schizophrenia Bulletin, 30(4), 713–726.